NEW YORK (360Dx) – Hennigsdorf, Germany-based Sphingotec said today that it has combined technology platforms with San Diego, California-based Nexus Dx to improve decision-making at the point of care in emergency departments and intensive care units.
Financial and other terms of the deal were not disclosed.
Holding company Polaris MediNet — jointly owned by Sphingotec and Nam Shin, CEO of Nexus Dx — merged the technology platforms.
The firms will market Sphingotec's CE-marked acute biomarkers proenkephalin (penKid) and adrenomedullin (bio-ADM) on the Nexus IB 10 immunoassay-based point-of-care testing platform. Sphingotec said that the biomarkers diagnose and monitor real-time kidney function and endothelial dysfunction, which can lead to septic shock and congestion that can lead to acute heart failure.
Clinicians doing point-of-care testing with the two biomarkers will be able to conduct on-site diagnosis and monitoring of sepsis, decongestive heart failure, and acute kidney injury in emergency departments and intensive care units, and provide guidance for therapies, Sphingotec said. The point-of-care platforms will enable emergency department physicians to run tests within a few minutes, operating from whole blood and without sample preparation, it added.
Sphingotec said that since 2017, Bestbion Dx has been distributing the bio-ADM and penKid immunoassays in Germany and Austria, and Shuwen Biotech has been marketing them under an agreement in China.
Andreas Bergmann, founder and CEO of Sphingotec, said in a statement that using the POC platform, the firm expects to soon start distributing its acute-care biomarkers in Europe to aid in monitoring and adjusting therapies.
The IB10 system is a microfluidic immunoassay platform which automatically separates plasma from whole blood for further analyses.